83 results
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
14 May 24
NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
4:10pm
million, compared with $3.5 million in the same period of the prior fiscal year. Research and Development (R&D) expense in the second quarter of fiscal 2024 …
Collaborations revenue
Operating expenses:
Selling, general and administrative
Research and development
Total operating expenses
Loss from operations
Other
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
15 Mar 24
Submission of Matters to a Vote of Security Holders
4:30pm
company developing minimally invasive products for obstructive lung diseases. Before that, he was a Senior Vice President of Research and Development
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
13 Feb 24
NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
4:15pm
of product revenue
Product gross profit (loss)
Collaborations revenue
Operating expenses:
Selling, general and administrative
Research and development
Total
8-K
EX-99.1
6pci0
14 Dec 23
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
4:30pm
8-K
EX-10.1
iwqwmm
14 Nov 23
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement
5:28pm
8-K
EX-99.1
ypktxjuyesd
14 Aug 23
NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
4:15pm
8-K
EX-99.1
owxu17jld3cbe
11 May 23
NeuroOne® Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
4:16pm
8-K
EX-99.1
q24lt
22 Dec 22
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2022 Financial Results
9:11am
8-K
EX-99.1
9bmwc3be nk
2 Jun 22
NeuroOne® Issues Letter to Stockholders in Connection With 2022 Annual Meeting of Stockholders
4:05pm